199730.KQ BioInfra Co., Ltd.
- Market cap
- KRW 6.57B
- P/E
- -
- P/B
- 0.52x
- ROE
- -39.6%
- Dividend yield
- 29.63%
- Fundamental score
- 0.7/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 199730.KQ undervalued?
Graham numberThe Graham number of BioInfra Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioInfra Co., Ltd. fundamental analysis
3 of 21 checks passedROE 0/2
Low return on equity (-39.6%), below 10%.
ROA 0/1
Return on assets (-14.6%) is below the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-129.7%) is below the industry median (4.8%).
Revenue Growth 0/2
Revenue shrank 13.2% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.9 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.5x) is below the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 2/2
Dividend yield (29.6%) is in the top 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
BioInfra Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioInfra Co., Ltd.
BioInfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. The company provides clinical, which undertakes clinical trials for new drug development approval (Phase I-III) and late clinical trials; immunoassay, which performs pharmacokinetic, toxicokinetic, and biomarker analysis of polymer biopharmaceuticals; and testing and inspection, which provides finished drug product quality inspection, comparative dissolution testing, and long-term st…
Full company profileBioInfra Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioInfra Co., Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 35.4B | 30.1B | 23.8B | 23.1B | 28.0B |
| Gross Profit | 14.0B | 9.55B | 5.70B | 5.32B | 6.59B |
| Operating Income | 6.36B | 1.31B | -5.12B | -6.27B | -4.67B |
| EBITDA | 9.34B | 4.09B | -2.18B | -4.32B | -1.09B |
| Net Income | 6.24B | 2.00B | -3.98B | -9.13B | -4.99B |
| EPS | 1,511 | 417 | -817 | -1,877 | -1,025 |
| Balance Sheet | |||||
| Total Assets | 32.6B | 47.0B | 41.1B | 35.0B | 34.2B |
| Total Liabilities | 14.7B | 13.0B | 13.6B | 18.5B | 21.6B |
| Shareholders' Equity | 17.9B | 34.0B | 27.6B | 16.5B | 12.6B |
| Cash & Short-term Investments | 7.36B | 10.7B | 4.03B | 2.14B | 2.83B |
| Cash Flow | |||||
| Operating Cash Flow | 8.42B | 679M | 1.73B | -1.50B | -2.94B |
| Capital Expenditure | 10.7B | 3.70B | 2.87B | 1.53B | 304M |
| Free Cash Flow | -2.26B | -3.02B | -1.14B | -3.03B | -3.25B |
| Ratios | |||||
| ROE | 34.8% | 5.9% | -14.4% | -55.4% | -39.6% |
| ROA | 19.1% | 4.3% | -9.7% | -26.1% | -14.6% |
| Net Profit Margin | 17.6% | 6.6% | -16.7% | -39.4% | -17.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BioInfra Co., Ltd. dividends
- Dividend yield
- 29.63%
- Forward dividend
- 300.00 KRW
- Payout ratio
- -
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 1.95B | 400 | - |
| 2024 | KRW 2.88B | 592 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns BioInfra Co., Ltd.
- Insiders 42.45%
- Institutions 0.00%
- Public & others 57.55%
- Shares outstanding 4.86M
- Free float 2.36M
BioInfra Co., Ltd. company profile
- Company name
- BioInfra Co., Ltd.
- Ticker
- 199730.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 120 Heungdeokjungang-ro, Yongin-si, South Korea
- Phone
- 82 3 1627 2800
- Website
- bioinfrakorea.co.kr
About BioInfra Co., Ltd.
BioInfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. The company provides clinical, which undertakes clinical trials for new drug development approval (Phase I-III) and late clinical trials; immunoassay, which performs pharmacokinetic, toxicokinetic, and biomarker analysis of polymer biopharmaceuticals; and testing and inspection, which provides finished drug product quality inspection, comparative dissolution testing, and long-term stability testing. It also specializes in bioequivalence testing of generic drugs, phase 1 clinical trials for new and improved drugs; and sample analysis services for new drug substances. The company was founded in 2007 and is based in Yongin-si, South Korea.
BioInfra Co., Ltd. management
2- Mr. Sangdeuk LeeCEO & Inside Director · born 1959
- YoungGuk LeeExecutive Inside Director